Biotest GmbH KGaA (LTS:0N6Z) Other Current Assets: £0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biotest GmbH KGaA Other Current Assets?

Biotest GmbH KGaA LTS:0N6Z Other Current Assets is £0.00 Mil as of . 20.

Biotest GmbH KGaA's other current assets for the quarter that ended in . 20 was £0.00 Mil.


Biotest GmbH KGaA Other Current Assets Related Terms


Biotest GmbH KGaA Other Current Assets Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA Other Current Assets Chart

Biotest GmbH KGaA Annual Data
Trend
Other Current Assets

Biotest GmbH KGaA Semi-Annual Data
Other Current Assets

Biotest GmbH KGaA Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of £0.00 Mil mean?
Biotest GmbH KGaA (LTS:0N6Z) has a Other Current Assets of £0.00 Mil as of . 20. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Biotest GmbH KGaA.
Is Biotest GmbH KGaA's Other Current Assets too high?
Biotest GmbH KGaA's current Other Current Assets is £0.00 Mil.
How does Biotest GmbH KGaA's Other Current Assets compare to ?
Biotest GmbH KGaA's Other Current Assets of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Biotest GmbH KGaA. Biotest GmbH KGaA's current Other Current Assets is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current Other Current Assets of £0.00 Mil. The current Other Current Assets is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current Other Current Assets is £0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.